Axitinib and Nivolumab for the Treatment of Mucosal Melanoma

Inclusion Criteria:

• Histologic diagnosis of unresectable or advanced mucosal melanoma arising from thehead/neck (e.g. sinonasal, oral cavity, conjunctival), gastrointestinal (e.g.anorectal, esophageal), or genitourinary (e.g. vulvovaginal, urethral) sites.

• Measurable disease

1. Initial study entry: Subjects must have at least 1 extracranial, unresectable,non-bony lesion that is measurable radiographically (based on RECIST 1.1).

2. Triplet arms: assessable disease required. RECIST 1.1 measurable disease is notrequired.

• Prior therapy

1. Initial study entry: No prior systemic therapy (adjuvant or metastatic).

2. Triplet arms: Only prior systemic therapy is nivolumab + axitinib on thistrial.

• ECOG performance status of 0-2.

• Asymptomatic untreated brain metastases are allowed. Symptomatic brain metastasesthat have undergone local therapy with RT or surgery and have not required anincrease in steroid dose in prior 2 weeks are allowed.

• Screening laboratory parameters:

1. White blood cell (WBC) count ≥ 2000/μL;

2. Absolute neutrophil count (ANC) ≥ 1500/μL;

3. Platelets ≥ 100,000/μL;

4. Hemoglobin (Hgb) ≥ 9 g/dL;

5. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3 × upperlimit of normal (ULN);

6. Total bilirubin ≤ 1.5 × ULN (< 3 mg/dL for subjects with Gilbert's disease);

7. Estimated glomerular filtration rate (GFR) ≥ 30 mL/min;either Cockcroft Gaultor a cancer-specific GFR Model such as the camGFR version 2 can be used;

• Age ≥ 18 years.

• Females of childbearing potential who are sexually active with a nonsterilized malepartner must use 2 methods of effective contraception from screening, and must agreeto continue using such precautions for 23 weeks after the final dose ofinvestigational product; cessation of birth control after this point should bediscussed with a responsible physician. Periodic abstinence, the rhythm method, andthe withdrawal method are not acceptable methods of birth control. [Females ofchildbearing potential are defined as those who are not surgically sterile (i.e.,bilateral tubal ligation, bilateral oophorectomy, or complete hysterectomy) orpostmenopausal (defined as 12 months with no menses without an alternative medicalcause).] Nonsterilized males who are sexually active with a female partner ofchildbearing potential must use 2 acceptable methods of effective contraception fromDay 1 and for 31 weeks after receipt of the final dose of investigational product.

Acceptable methods of effective contraception are described in the following:

• Barrier Methods (Male condom plus spermicide, cap plus spermicide, or diaphragm plusspermicide).

• Intrauterine Device Methods (Copper T, or Levonorgestrelreleasing intrauterinesystem (e.g., Mirena®), also considered a hormonal method).

• Hormonal Methods (Implants, hormone shot or injection, combined pill, mini pill, orPatch).

Exclusion Criteria:

• Active autoimmune disease or any condition requiring systemic treatment with eithercorticosteroids (>10 mg daily of prednisone equivalents) or other immunosuppressivemedications within 14 days of study drug administration. Inhaled or topical steroidsand adrenal replacement doses > 10 mg daily prednisone equivalents are permitted inthe absence of active autoimmune disease.

• History of motor neuropathy considered to be of autoimmune origin (e.g., Guillain-Barre Syndrome, Myasthenia Gravis).

• History of myocarditis.

• History of, or any active evidence of non-infectious pneumonitis

• Other active, concurrent malignancy that requires ongoing systemic treatment orinterferes with radiographic assessment of melanoma response as determined by theinvestigator.

• Cardiovascular disease, including:

• History of acute coronary syndromes (including myocardial infarction andunstable angina), coronary artery bypass graft (CABG) coronary angioplasty, orstenting within 6 months prior to study entry.

• Current Class II or higher congestive heart failure as defined by the New YorkHeart Association (NYHA) functional classification system.

• Treatment-refractory hypertension defined as a blood pressure of systolic >150mmHg and/or diastolic >90 mmHg despite adequate attempts at antihypertensivetherapy.

• Underlying hematologic issues including:

• Congenital bleeding diathesis

• GI bleeding requiring intervention within the past 6 months

• Active hemoptysis within 42 days prior to study enrollment

• Pulmonary emboli or deep vein thromboses (DVT) that are not stable onanticoagulation regimen.

• History of severe allergic reactions to an unknown allergen or any components of thestudy drugs.

• Other serious infectious illnesses (e.g., active symptoms of COVID-19 infection or apost-infectious symptomatic autoimmune syndrome, serious bacterial infectionsrequiring antibiotics).

• Women who are breastfeeding or who are pregnant as evidenced by a positive serumpregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) performedwithin 14 days of the first dose of study drug and by a urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) within 24 hours of thefirst dose of study drug(s).

• Genetic or autoimmune condition causing heightened radio sensitivity.